Frontal Fibrosing Alopecia

Overview

Frontal fibrosing alopecia (FFA) is a form of scarring alopecia characterised by progressive recession of the frontal and temporal hairline. It is classified as a subtype of lichen planopilaris (LPP), a lymphocytic cicatricial alopecia in which inflammation targets the hair follicles, ultimately leading to permanent follicular destruction and irreversible hair loss.

FFA predominantly affects postmenopausal women, although cases have been reported in premenopausal women and, less commonly, in men. The condition has been increasingly recognized over recent decades, with a notable rise in incidence that has generated considerable research interest. FFA was first described in 1994 and is now considered one of the most common causes of scarring alopecia seen in dermatology practice.

Causes and Risk Factors

The exact cause of frontal fibrosing alopecia is not fully understood, but the condition is considered to have an autoimmune basis. A lymphocytic inflammatory infiltrate targets the hair follicle bulge region, which houses the follicular stem cells. Destruction of these stem cells results in permanent scarring and loss of the hair follicle.

Several factors have been associated with the development of FFA:

• Hormonal factors: the strong predilection for postmenopausal women suggests a role for hormonal changes, particularly declining oestrogen levels, in disease susceptibility
• Environmental triggers: epidemiologic studies have explored associations with sunscreen use, leave-on facial skincare products, and other topical exposures, though a definitive causal relationship has not been established
• Genetic susceptibility: familial clustering has been observed, and genome-wide association studies have identified genetic loci that may contribute to disease risk
• Autoimmune associations: FFA has been reported in association with other autoimmune conditions, including thyroid disease and vitiligo

Signs and Symptoms

The hallmark of frontal fibrosing alopecia is progressive, symmetrical recession of the frontal and temporal hairline. The recession typically produces a band-like area of pale, smooth, scarred skin along the former hairline. Key clinical features include:

• Gradual recession of the frontal hairline, often by several centimetres over months to years
• Perifollicular erythema and scaling at the active margin of hair loss, indicating ongoing inflammation
• Loss of eyebrows, which may precede or accompany the scalp hair loss and is present in the majority of affected individuals
• Loss of body hair, including eyelashes, arm hair, and leg hair
• The "lonely hair" sign, in which isolated terminal hairs persist within the band of scarred, hairless skin
• Facial papules along the hairline, which represent vellus hair involvement

Some patients report mild itching, tightness, or tenderness in the affected areas. The condition is slowly progressive, and without treatment, hairline recession may continue over years.

Diagnosis

The diagnosis of frontal fibrosing alopecia is based on the characteristic clinical pattern of hairline recession combined with histopathologic confirmation. A skin biopsy taken from the active margin of hair loss typically reveals a lichenoid lymphocytic inflammatory infiltrate surrounding and targeting the hair follicles, with perifollicular fibrosis and follicular destruction. These findings are histologically identical to lichen planopilaris.

Dermoscopic examination of the scalp can reveal additional features, including perifollicular scaling, loss of follicular openings in the scarred area, and perifollicular erythema at the active edge. Trichoscopy assists in distinguishing FFA from other forms of alopecia. Blood tests may be performed to screen for associated autoimmune conditions, particularly thyroid disease.

Treatment Options

Treatment of frontal fibrosing alopecia aims to halt disease progression and preserve remaining hair. Because the scarring process permanently destroys hair follicles, hair that has already been lost cannot be regrown. Early diagnosis and treatment are therefore critical to achieving the best possible outcome.

Prescription management of FFA typically involves a combination of anti-inflammatory and immunomodulatory agents. Treatment options include:

• Hydroxychloroquine, an antimalarial agent with anti-inflammatory properties, is one of the most commonly used systemic treatments for FFA
• Topical and intralesional corticosteroids to reduce active inflammation at the hairline margin
• 5-alpha reductase inhibitors (finasteride or dutasteride), which have shown benefit in stabilising disease progression in some patients
• Topical calcineurin inhibitors (tacrolimus) as adjunctive anti-inflammatory therapy
• Oral retinoids or doxycycline in selected cases

Treatment is typically continued for an extended period, as discontinuation may lead to disease reactivation. A dermatology consultation allows for individualized assessment and development of a treatment plan tailored to disease severity and patient factors.

When to Seek Medical Attention

Any progressive recession of the hairline, particularly when accompanied by loss of eyebrows or body hair, should prompt evaluation by a dermatologist. Early intervention is important because treatment can halt further progression but cannot reverse scarring that has already occurred. The earlier treatment is initiated, the more hair can be preserved.

A referral from a family physician is typically required to access dermatology services at the Centre for Medical and Surgical Dermatology. Dr. Maksym Breslavets provides specialist evaluation and management of complex hair loss conditions, including frontal fibrosing alopecia.